Tags

Type your tag names separated by a space and hit enter

Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
Bull World Health Organ. 2001; 79(7):625-31.BW

Abstract

OBJECTIVE

To test the efficacy of locally produced Vi vaccine over a time period of longer than one year.

METHODS

A double-blinded, randomized field trial was performed in Guangxi Zhuang Autonomous Region in south-western China, using 30 micrograms doses of locally produced Vi. Enrolled subjects were 3-50 years of age, although the majority (92%) were school-aged children, who have the highest rate of typhoid fever in this setting. A total of 131,271 people were systematically allocated a single dose of 30 micrograms of Vi polysaccharide or saline placebo. The study population was followed for 19 months, with passive surveillance conducted in the Ministry of Health and the Regional Health and Anti-epidemic Centre (HAEC). Clinically suspected cases of typhoid fever were confirmed by blood culture, or by serological reaction with O-antigen (Widal tests).

FINDINGS

After 19 months, there were 23 culture-confirmed cases of typhoid fever in the placebo group versus 7 cases in the Vi group (Protective efficacy (PE) = 69%; 95% CI = 28%, 87%). Most of the isolates were from school-aged children: 22 cases in the placebo group versus 6 in the Vi group (PE = 72%; 95% CI = 32%, 82%). No serious post-injection reactions were observed. The locally produced Vi polysaccharide vaccine showed levels of protective efficacy similar to those for Vi vaccine produced in industrial countries.

CONCLUSION

The slightly higher dose of vaccine did not seem to alter efficacy significantly in China.

Authors+Show Affiliations

Guangxi Health and Anti-epidemic Centre (GHAEC), 80 Taoyuan Road, Nanning, Guangxi 530021, China. honghy@public.nn.gx.cnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11477965

Citation

Yang, H H., et al. "Efficacy Trial of Vi Polysaccharide Vaccine Against Typhoid Fever in South-western China." Bulletin of the World Health Organization, vol. 79, no. 7, 2001, pp. 625-31.
Yang HH, Wu CG, Xie GZ, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ. 2001;79(7):625-31.
Yang, H. H., Wu, C. G., Xie, G. Z., Gu, Q. W., Wang, B. R., Wang, L. Y., Wang, H. F., Ding, Z. S., Yang, Y., Tan, W. S., Wang, W. Y., Wang, X. C., Qin, M., Wang, J. H., Tang, H. A., Jiang, X. M., Li, Y. H., Wang, M. L., Zhang, S. L., & Li, G. L. (2001). Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bulletin of the World Health Organization, 79(7), 625-31.
Yang HH, et al. Efficacy Trial of Vi Polysaccharide Vaccine Against Typhoid Fever in South-western China. Bull World Health Organ. 2001;79(7):625-31. PubMed PMID: 11477965.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. AU - Yang,H H, AU - Wu,C G, AU - Xie,G Z, AU - Gu,Q W, AU - Wang,B R, AU - Wang,L Y, AU - Wang,H F, AU - Ding,Z S, AU - Yang,Y, AU - Tan,W S, AU - Wang,W Y, AU - Wang,X C, AU - Qin,M, AU - Wang,J H, AU - Tang,H A, AU - Jiang,X M, AU - Li,Y H, AU - Wang,M L, AU - Zhang,S L, AU - Li,G L, PY - 2001/8/2/pubmed PY - 2001/8/24/medline PY - 2001/8/2/entrez SP - 625 EP - 31 JF - Bulletin of the World Health Organization JO - Bull World Health Organ VL - 79 IS - 7 N2 - OBJECTIVE: To test the efficacy of locally produced Vi vaccine over a time period of longer than one year. METHODS: A double-blinded, randomized field trial was performed in Guangxi Zhuang Autonomous Region in south-western China, using 30 micrograms doses of locally produced Vi. Enrolled subjects were 3-50 years of age, although the majority (92%) were school-aged children, who have the highest rate of typhoid fever in this setting. A total of 131,271 people were systematically allocated a single dose of 30 micrograms of Vi polysaccharide or saline placebo. The study population was followed for 19 months, with passive surveillance conducted in the Ministry of Health and the Regional Health and Anti-epidemic Centre (HAEC). Clinically suspected cases of typhoid fever were confirmed by blood culture, or by serological reaction with O-antigen (Widal tests). FINDINGS: After 19 months, there were 23 culture-confirmed cases of typhoid fever in the placebo group versus 7 cases in the Vi group (Protective efficacy (PE) = 69%; 95% CI = 28%, 87%). Most of the isolates were from school-aged children: 22 cases in the placebo group versus 6 in the Vi group (PE = 72%; 95% CI = 32%, 82%). No serious post-injection reactions were observed. The locally produced Vi polysaccharide vaccine showed levels of protective efficacy similar to those for Vi vaccine produced in industrial countries. CONCLUSION: The slightly higher dose of vaccine did not seem to alter efficacy significantly in China. SN - 0042-9686 UR - https://www.unboundmedicine.com/medline/citation/11477965/Efficacy_trial_of_Vi_polysaccharide_vaccine_against_typhoid_fever_in_south_western_China_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/11477965/ DB - PRIME DP - Unbound Medicine ER -